Daiichi Sankyo Company, Limited

Ngk Spark Plug Company, Limited

National Institutes of Biomedical Innovation, Health and Nutrition

Subaru Corporation

Sankyo Company, Limited

Yuji Kasuya

Hideki Miyazaki

Kazuhiro Yoshida

Takeshi Masuda

Hiroyuki Naito

Masao Yoshida

Takashi Nakada

Yuki Abe

Shinji Ashida

Yusuke Ogitani

Koji Morita

Makoto Koizumi

Takako Niwa

Yoshiyuki Onishi

Ichiro Hayakawa

Masakazu Tamura

Ken Ishii

Yasunori Ono

Tatsuya Inoue

Satoshi Komoriya

Yasuhiro Nakagami

Emiko Hatano

Kayoko Masuda

Mayumi Iizuka

Takashi Ohnuki

Kouji Kobiyama

Atsunobu Sakamoto

Taiki Aoshi

Yoko Murakami

Masako Minami

Masaru Iwasaki

Fumihiko Takeshita

Kenji Ban

Masahiro Inoue

Yoshikazu Kataoka

Noboru Matsumoto

Masashi Honma

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L-L-L-NH—(CH)n-L-L-L- wherein the antibody is connected to the terminal of L, and the antitumor compound is connected to the terminal of Lwith the nitrogen atom of the amino group at position 1 as a connecting position.

Antibody-drug conjugate

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L-L-L-NH&#x2014;(CH)n-L-(CH)n-C(&#x2550;O)&#x2014; wherein the anti-HER2 antibody is connected to the terminal L, and the antitumor compound is connected to the carbonyl group of the &#x2014;(CH)n-C(&#x2550;O)&#x2014; moiety with the nitrogen atom of the amino group at position 1 as the connecting position

Method for treating cancer comprising administration of anti-HER2 antibody-drug conjugate

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L-L-L-NH&#x2014;(CH)n-L-L-L- wherein the antibody is connected to the terminal of L, and the antitumor compound is connected to the terminal of Lwith the nitrogen atom of the amino group at position 1 as a connecting position.

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L-L-L-NH&#x2014;(CH)n-L-(CH)n-C(&#x2550;O)&#x2014; wherein the anti-HER2 antibody is connected to the terminal L, and the antitumor compound is connected to the carbonyl group of the &#x2014;(CH)n-C(&#x2550;O)&#x2014; moiety with the nitrogen atom of the amino group at position 1 as the connecting position. 

Method of treating cancer comprising administration of anti-HER2 antibody-drug conjugate

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L-L-L-NH&#x2014;(CH)n-L-L-Lor -L-L-L- wherein the anti-HER2 antibody is connected to the terminal L, and the antitumor compound is connected to the terminal Lor Lwith the nitrogen atom of the amino group at position 1 as the connecting position. 

(Anti-HER2 antibody)-drug conjugate

The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3'-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and &#x3b2;-1,3-glucan.

Complex containing oligonucleotide having immunopotentiating activity and use thereof

The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.

Sustained-release pharmaceutical composition for treatment and prevention of eye disease

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L-L-L-NH&#x2014;(CH)n-L-L-L- or -L-L-L- wherein the antibody is connected to the terminal of L, the antitumor compound is connected to the terminal of Lor L, and any one or two or more of linkers of L, L, and Lhas a hydrophilic structure.

Antibody-drug conjugate produced by binding through linker having hydrophilic structure

The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.

Cationic lipid

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula:-L-L-L-NH&#x2014;(CH)-L-L-L-wherein the antibody is connected to the terminal of L, and the antitumor compound is connected to the terminal of Lwith the nitrogen atom of the amino group at position 1 as a connecting position.

Anti-HER2 antibody-drug conjugate

Growing community of inventors

Tokyo, Japan

Yuji Kasuya